Health Care · Pharmaceutical Preparations

NGNE Neurogene Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1404644126 filings
Russell 2000

NGNE at a glance

Neurogene Inc. (NGNE, SEC CIK 1404644) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Neurogene Inc. (NGNE) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $90.4 million. Diluted EPS was -$4.24.
  • As of September 30, 2026, 21 institutional investment managers tracked by SignalX reported holding Neurogene Inc. (NGNE) shares worth $122.9 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Cvijic Christine Mikail on July 7, 2026 of 4,200 shares at $36.13 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$0
−100.0% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
21 funds
$122.9M · −3 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • No product revenue, unchanged from prior-year quarter; net loss $29.0M vs $21.0M YoY
  • Operating margin not applicable, operating loss $32.4M vs $23.8M YoY
  • Rett syndrome program largest expense, $8.9M vs $5.6M YoY
  • Cash, equivalents and short-term investments $359.7M; operating cash use $79.0M nine-month period
  • July offering raised $134.9M; runway extended into first quarter of 2029, topline NGN-401 data expected second half 2027

Risk Factors

  • Newly emphasized regulatory risk: FDA denied NGN-101’s RMAT designation, removing the streamlined registrational pathway and potentially ending further investment
  • Most material clinical update: NGN-401’s 3E15 vg dose was removed after a November 2024 fatal SAE, with additional safety monitoring added
  • Operational risk: NGN-401 remains dependent on successful Embolden trial execution after dosing completion in the second quarter of 2026
  • Financial risk: $447.1 million cumulative net loss, with existing cash expected to fund operations into the first quarter of 2029
  • Supply-chain risk: U.S. tariffs and BIOSECURE Act restrictions could disrupt Chinese biotechnology relationships and increase material costs

AI summary of the NGNE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Updated corporate presentation highlights current corporate and investor messaging

Item EX-99.1: Item EX-99.1

  • Embolden topline data expected 2H 2027, with 25 participants in primary efficacy analysis and a 9-of-25 success threshold
  • NGN-401 1E15 vg dose generally well-tolerated across 35 participants as of November 8, 2026

Item EX-99.2: Item EX-99.2

  • Embolden registrational trial fully dosed, N=25, exceeding target enrollment and supporting a potential broad age label for patients ≥3 years
  • Topline Embolden data expected 2H 2027, the key clinical catalyst for NGN-401’s potential approval
Filed Aug 11, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Phase 1/2 efficacy signal strengthened: 100% of participants improved on CGI-I and gained milestones, averaging 4.7 each through 30 months
  • NGN-401 safety remained generally well-tolerated at 1E15 vg across 35 participants, supporting continued registrational development

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Updated corporate presentation provides investors with refreshed company and pipeline information

Item EX-99.2: Item EX-99.2

  • Embolden registrational trial fully dosed with 25 participants, supporting a single-trial BLA strategy for females aged ≥3 years
  • Phase 1/2 data: 100% of 10 participants gained milestones, 80% met the composite responder definition, with 4.7 average gains
Filed Jul 2, 2026Full analysis →

Item 8.01: Other Events

  • Offering proceeds extend Neurogene’s funding runway through the first quarter of 2029
  • Combined liquidity expected to cover operating expenses and capital expenditures

Item 1.01: Entry into a Material Definitive Agreement

  • $134.8M expected net proceeds from equity offering, strengthening Neurogene’s cash position
  • 3.5M common shares sold at $30.00 plus pre-funded warrants for 666,666 shares

AI summaries of NGNE 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for NGNE

Don't miss the next NGNE filing

  • Alerts as it files. A push when NGNE files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut NGNE, by share count.
  • Ask anything. An AI agent that reads every NGNE filing and answers with sources.

NGNE alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
McMinn RachelMSep 22, 2026-
McMinn RachelMSep 22, 2026$25.32
Cvijic Christine MikailSellJul 7, 2026$36.13
Cvijic Christine MikailSellJul 6, 2026$36.02
Cvijic Christine MikailSellJul 2, 2026$35.23
Cvijic Christine MikailSellJul 2, 2026$34.58
Cvijic Christine MikailSellJul 2, 2026$35.23
Cvijic Christine MikailSellJul 2, 2026$34.58

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$925K$0
Operating Income-$55.6M-$82.6M-$103.3M
Net Income--$75.1M-$90.4M
Op. Margin--8930.3%-
Net Margin--8123.7%-
Balance Sheet
Total Assets-$335.7M$288.6M
Equity-$310.4M$264.9M
ROE--24.2%-34.1%
Per Share
EPS$2.93$-4.28$-4.24
Cash Flow
Operating CF-$51.4M-$70.6M-$77.2M
CapEx$321K$808K$1.2M

Source: XBRL data in Neurogene Inc. (NGNE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate NGNE share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
NGNE shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202621$122.9M
Q2 202624$109.5M
Q1 202621$71.6M
Q4 202520$67.1M
Q3 202516$49.0M
Q2 202517$50.7M
Q1 202516$25.1M
Q4 202412$43.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 147 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

NGNE filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 9, 2026Analysis
8-KNov 9, 2026Analysis-
4Oct 2, 2026--
SC 13GAug 14, 2026-
8-KAug 11, 2026Analysis-
10-QAug 11, 2026Analysis
4Jul 7, 2026--
4Jul 2, 2026--
8-KJul 2, 2026Analysis-
8-KJun 29, 2026Analysis-
4Jun 16, 2026--
4Jun 16, 2026--
4Jun 16, 2026--
8-KJun 8, 2026Analysis
8-KJun 4, 2026Analysis
10-QMay 12, 2026Analysis
8-KMay 12, 2026Analysis
4May 8, 2026-
4May 7, 2026-
8-KApr 20, 2026Analysis-
4Mar 30, 2026--
4Mar 30, 2026--
4Mar 30, 2026--
10-KMar 24, 2026-
8-KMar 24, 2026--

Related Health Care companies

All Health Care →

NGNE SEC filings: frequently asked questions

Which institutions hold NGNE stock?

As of September 30, 2026, the largest Neurogene Inc. (NGNE) holders among the 13F filers tracked by SignalX were BlackRock ($41.0 million), Vanguard Capital Management LLC ($19.8 million), Franklin Resources ($17.4 million), State Street Corp ($15.3 million), Morgan Stanley ($6.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was NGNE's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Neurogene Inc. (NGNE) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $90.4 million. Diluted EPS was -$4.24. The figures come from the XBRL data in the 10-K.

What did NGNE report in its latest 8-K?

Neurogene Inc. (NGNE) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest NGNE SEC filings?

Neurogene Inc. (NGNE) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on October 2, 2026.

What is NGNE's SEC CIK number?

Neurogene Inc. (NGNE)'s SEC Central Index Key (CIK) is 1404644. EDGAR lists every NGNE filing under that number.

Ask anything about NGNE

The research agent reads NGNE's filings, financials, insider trades and 13F holders, then answers with sources.